A 5-year sensitivity analysis of a recent trial showed improved efficacy outcomes and toxicity profiles for patients receiving a new adjuvant therapy for HER2-positive breast cancer. READ MORE

Research in Review

Use of the 21-gene recurrence score assay (RS) can help to reduce health care spending and improve breast cancer treatment, but the extent of the benefit offered differs between younger women and those aged 75 years and older.

READ MORE

An observational study of more than 100,000 women with a diagnosis of ductal carcinoma in situ (DCIS, or Stage 0 breast cancer) and published in JAMA Oncology, showed that age and ethnicity are important risk factors for death from breast cancer following a DCIS diagnosis, according to findings that estimated the 10- and 20-year mortality in this patient population. 

READ MORE